Loading...

VERU VERU INC Operational Disruptions 8-K Filing

VR N

VR

VERU INC

(VERU)

2023 8-K

Show Summary

Show Summary

Earnings Releases

Equity Plan Update

Nasdaq Deficiency

Quarterly Results

Forbearance Agreement

Nasdaq Compliance

Earnings Reports

Appointment of Director

Adjournment of Annual Meeting

Dismissal of Independent Re...

Earnings Report

Compliance regained with Na...

Financial Restatement

Earnings Report

Purchase Agreement Amendment

Financial Restatement

Amendment to Asset Purchase...

Clinical Data Announcement

Earnings Reports

Amendment to Articles of In...

Open Market Sale Agreement

Earnings Reports

Purchase Agreement with Lin...

Asset Purchase Agreement

Stock Purchase Agreement

External Links:

VERU INC. announced clinical data from its discontinued Phase 3 ARTEST clinical trial of enobosarm monotherapy for the 3rd line or greater in the metastatic setting of AR+ER+HER2- breast cancer.

AI Assistant

VERU INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.